Diuretic therapy remains a vital cog in the management of hypertension; either as monotherapy or in combination with other antihypertensive classes. However, maximizing the antihypertensive effect of ...

Each year 1 million Americans are diagnosed with heart failure, a serious condition that causes shortness of breath, weakness, and excess fluid. Diuretics are the main therapy for fluid removal but ...

SGLT2 inhibitors represent one of the most remarkable therapeutic developments in heart failure care, transitioning from ...

The US Food and Drug Administration (FDA) has approved the first intranasal diuretic for heart, liver and kidney disease patients, aiming to prevent a common and costly issue that results in more than ...

CHICAGO -- The choice between furosemide and torsemide didn't matter for longer-term clinical outcomes of hospitalized heart failure patients, according to the comparative effectiveness trial ...

Please provide your email address to receive an email when new articles are posted on . Researchers found a notable interaction based on patients' prior history of kidney stones. Hypokalemia was more ...

In the chronic response phase of therapy the vasodepressor influence of a diuretic emerges as a process driven by a reduction in total peripheral resistance (TPR), which is inadequately explained ...

A Nevada-based biopharmaceutical company Corstasis Therapeutics has received approval from the US Food and Drug Administration for the bumetanide nasal spray, which could be useful in the treatment of ...